Due the CD99 and MIF signaling pathways both having a prominent function in cell adhesion, migration, survival and death, the therapy targeting for XCL1+ CD8+ T cells might be an efficient treatment to improve prognosis of HCC. This evidence concerns the gene CD8A and hepatocellular carcinoma.